Compare PFSI & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFSI | AMRX |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.0B |
| IPO Year | 2018 | 2018 |
| Metric | PFSI | AMRX |
|---|---|---|
| Price | $82.38 | $16.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $128.11 | $15.60 |
| AVG Volume (30 Days) | 471.9K | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | 59.25 | ★ 157.89 |
| EPS | ★ 1.53 | 0.19 |
| Revenue | ★ $984,629,000.00 | N/A |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | $16.96 | $7.13 |
| P/E Ratio | ★ $53.92 | $84.29 |
| Revenue Growth | ★ 3.05 | N/A |
| 52 Week Low | $77.67 | $7.67 |
| 52 Week High | $160.36 | $16.61 |
| Indicator | PFSI | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.84 | 78.56 |
| Support Level | $77.67 | $12.46 |
| Resistance Level | $88.65 | N/A |
| Average True Range (ATR) | 2.52 | 0.57 |
| MACD | 0.27 | 0.27 |
| Stochastic Oscillator | 58.03 | 90.29 |
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform mainly focused on the production and servicing of U.S. residential mortgage loans. The firm is also engaged in managing investments related to the U.S. mortgage market and provides products and services that leverage technologies to support customers. The company operates through two reportable operating segments: production and servicing. The production segment performs loan origination, acquisition, and sale activities, while the servicing segment performs servicing and subservicing of loans, early buyout transactions, and servicing of loans sourced and managed for PMT. The majority of revenue comes from the production segment.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.